John Duncan Higgons
Président chez Akamis Bio Ltd.
Profil
John Duncan Higgons is currently the Chairman at Akamis Bio Ltd.
and the Director at Rheos Medicines, Inc. He previously worked as a Director at Aras Corp., an Independent Director at Jounce Therapeutics, Inc., a Director at Auron Therapeutics, Inc., the SVP-Marketing & Business Development at Alkermes, Inc., the SVP-Business Development & Marketing at Eli Lilly & Co., the Executive Vice President-Business Operations at Archemix Corp., the Chief Operating Officer at Agios Pharmaceuticals, Inc., and the Chief Commercial Officer at TransForm Pharmaceuticals, Inc. He has a graduate degree from London Business School and an undergraduate degree from King's College London.
Postes actifs de John Duncan Higgons
| Sociétés | Poste | Début |
|---|---|---|
Akamis Bio Ltd.
 Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Président | - |
Rheos Medicines, Inc.
 Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Directeur/Membre du Conseil | 10/10/2018 |
Anciens postes connus de John Duncan Higgons
| Sociétés | Poste | Fin |
|---|---|---|
| JOUNCE THERAPEUTICS, INC. | Directeur/Membre du Conseil | 31/12/2022 |
| AGIOS PHARMACEUTICALS, INC. | Directeur des opérations | 15/01/2016 |
Archemix Corp.
 Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Directeur Général | - |
Auron Therapeutics, Inc.
 Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Directeur/Membre du Conseil | - |
Aras Corp.
 Aras Corp. Information Technology ServicesTechnology Services Aras Corp. provides enterprise open source software solutions. It offers PLM software solutions that enable companies to improve innovation, collaboration and coordination on a global scale. The firm's comprehensive applications address a wide range of strategic business initiatives across the entire product life cycle, includes program management, product engineering and quality planning. The company was founded by Peter H. Schroer in 2000 and is headquartered in Andover, MA. | Directeur/Membre du Conseil | - |
Formation de John Duncan Higgons
| London Business School | Graduate Degree |
| King's College London | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| AGIOS PHARMACEUTICALS, INC. | Health Technology |
| ELI LILLY AND COMPANY | Health Technology |
| Entreprise privées | 8 |
|---|---|
Archemix Corp.
Archemix Corp. Miscellaneous Commercial ServicesCommercial Services Archemix Corp. engages in the research and development of aptamer-based therapeutic products. It focuses in the areas of cardiovascular disease hematology, and oncology. The company was founded in May 2001 and is headquartered in Cambridge, MA. | Commercial Services |
TransForm Pharmaceuticals, Inc.
 TransForm Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology TransForm Pharmaceuticals, Inc. develops and manufactures drugs. It integrates pharmaceutical sciences, materials science and high throughput experimentation by enabling novel technology. The company was founded by Nicholas Galakatos in 1999 and is headquartered in Lexington, MA. | Health Technology |
Alkermes, Inc.
 Alkermes, Inc. Pharmaceuticals: MajorHealth Technology Alkermes, Inc. develops and manufactures pharmaceutical products. It offers medicines for the treatment of central nervous system (CNS) diseases. The company was founded by Michael A. Wall, Floyd E. Bloom, Frederick W. K. Brown, Paul R. Schimmel and Alexander G. Rich in 1987 and is headquartered in Waltham, MA. | Health Technology |
Jounce Therapeutics, Inc.
 Jounce Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Jounce Therapeutics, Inc. is a clinical stage immunotherapy company, which engages in developing treatments for cancer. It also provides novel cancer immunotherapies to attack tumors. The company was founded by Louis M. Weiner, Drew M. Pardoll, Thomas F. Gajewski, James P. Allison, Robert Schreiber, and Padmanee Sharma in 2013 and is headquartered in Cambridge, MA. | Commercial Services |
Akamis Bio Ltd.
Akamis Bio Ltd. BiotechnologyHealth Technology Akamis Bio Ltd. operates as a biotechnology company which develops novel therapeutics that addresses cancer and other clinically unmet diseases. Its products include Enadenotucirev, Espindolol and AbEnAd. The firm also develops treatments based upon the research phase vaccine platform PolySTAR, which combines recombinant viral vectors with polymers to shield them from the immune system, and the research phase adjuvant and immunotherapeutic platform PolyMAP, which combines polymers with synthetic adjuvants to significantly enhance the effectiveness of vaccines. The company was founded by Andrew Justin Stewart Coats and Stefan D. Anker on November 17, 2006 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Aras Corp.
Aras Corp. Information Technology ServicesTechnology Services Aras Corp. provides enterprise open source software solutions. It offers PLM software solutions that enable companies to improve innovation, collaboration and coordination on a global scale. The firm's comprehensive applications address a wide range of strategic business initiatives across the entire product life cycle, includes program management, product engineering and quality planning. The company was founded by Peter H. Schroer in 2000 and is headquartered in Andover, MA. | Technology Services |
Rheos Medicines, Inc.
Rheos Medicines, Inc. BiotechnologyHealth Technology Rheos Medicines, Inc. operates as a biopharmaceutical firm. It develops novel medicines that modulate metabolic pathways in immune cells to treat disease. The company was founded by Erika Pearce, Edward Pearce, Laurence Turka, Richard Flavell, Ken Smith, and E. William St. Clair and is headquartered in Cambridge, MA. | Health Technology |
Auron Therapeutics, Inc.
Auron Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Auron Therapeutics, Inc. operates as a biotechnology company. It aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. The company was founded by Kate Yen, Matt Vander Heiden, Ross Levine, and Eytan Stein and is headquartered in Wellesley, MA. | Commercial Services |
